442 related articles for article (PubMed ID: 22836736)
1. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
Wack LJ; Mönnich D; van Elmpt W; Zegers CM; Troost EG; Zips D; Thorwarth D
Acta Oncol; 2015; 54(9):1370-7. PubMed ID: 26203928
[TBL] [Abstract][Full Text] [Related]
3.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
4. Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial.
Zegers CM; van Elmpt W; Szardenings K; Kolb H; Waxman A; Subramaniam RM; Moon DH; Brunetti JC; Srinivas SM; Lambin P; Chien D
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1840-9. PubMed ID: 26136164
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
7. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
8. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
12. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
[TBL] [Abstract][Full Text] [Related]
13. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
[TBL] [Abstract][Full Text] [Related]
15. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S
PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586
[TBL] [Abstract][Full Text] [Related]
16. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
[TBL] [Abstract][Full Text] [Related]
17. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
Zegers CM; van Elmpt W; Hoebers FJ; Troost EG; Öllers MC; Mottaghy FM; Lambin P
Acta Oncol; 2015; 54(9):1378-84. PubMed ID: 26213313
[TBL] [Abstract][Full Text] [Related]
18. FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Zimny M; Gagel B; DiMartino E; Hamacher K; Coenen HH; Westhofen M; Eble M; Buell U; Reinartz P
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1426-31. PubMed ID: 16841141
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Grkovski M; Schöder H; Lee NY; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
J Nucl Med; 2017 Jul; 58(7):1072-1080. PubMed ID: 28183993
[TBL] [Abstract][Full Text] [Related]
20. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]